As we know that IL-1β is an important cytokine released by M1 macrophage, a clinical trial demonstrates that targeting on IL-1β by canakinumab can lower the incidence of AF recurrence after electrical cardioversion in the patients with heart diseases (174). This evidence concerns the gene IL1B and atrial fibrillation.